BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment

NCT00632749 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: BI 811283 (d 1 and 15)
DRUG: Cytarabine
DRUG: BI 811283 (d1)
DRUG: Cytarabine

Sponsor

Boehringer Ingelheim